1. The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS Society Conference July 18, 2010

2. A Time of Unprecedented Scientific Progress… And Fiscal Constraint

3. Policy Priorities in this Climate To sustain an enabling environment for continued AIDS vaccine innovation Identifying and addressing obstacles to scientific innovation Developing new financing and incentive mechanisms for global health R&D Demonstrating the value of an AIDS vaccine; advocating for strengthened political and financial support Demonstrating the value of an AIDS vaccine; advocating for strengthened political and financial support Harnessing AIDS vaccine investments for economic development

4. Identifying and Addressing Obstacles to Scientific Innovation ObstaclesRecommendations Product development capacity is limited Stimulate capacity through innovative public investment strategies targeting public and private producers Excessive regulatory review times and multiple conflicting regulatory requirements slow product development Decrease review times through enhanced administrative support; Catalogue and disseminate regulatory requirements Enhancing Brazil’s Capacity for Biopharmaceutical Innovation Brazilian STD, AIDS and Hepatitis Department Chinese Ministry of Health

5. Urgent need to accelerate AIDS vaccine R&D Need for innovative approaches and new thinking ? ? ? The state of the AIDS vaccine field  Establish a community of solvers  Accelerate the time it takes to solve the problem;  Allow for multiple approaches to achieve the same goal Prize competitions could…  Generate excitement and publicity and elevate the profile of the field;  Cast a wide net to attract participants from outside the field of interest; Identifying and Addressing Obstacles to Scientific Innovation Urgent need to accelerate AIDS vaccine R&D

6. Demonstrating the Value of an AIDS Vaccine Key findings:  Even with full scale-up of existing prevention and treatment, new HIV infections will persist in developing countries  An AIDS vaccine with 50% efficacy given to 30% of the adult population would avert 24% of new infections 2015- 2030, or 5.6 million  Preliminary findings suggest that an AIDS vaccine would be cost saving. Potential Impact of an AIDS Vaccine in Developing Countries Makerere Univ. School of Public Health Kenya AIDS Vaccine Initiative Evandro Chagas Clinical Research Inst.

7. Traditional funding for AIDS vaccine R&D is:  Insufficient  Unpredictable  Inflexible  Short-term New financing mechanisms could be designed to bring additional resources and accelerate global health R&D by:  Accessing funding from untapped resources  Mitigating political and economic shocks  Making future economic value of products available now  Supporting scientific risk-taking  Creating flexibility to facilitate rapid change of direction as new science emerges Developing New Financing Mechanisms to Advance Global Health R&D Policy priorities:  Develop a financing mechanism for global health R&D, or AIDS vaccine R&D  Expand existing mechanisms to include R&D

8. Investments in AIDS vaccine R&D can contribute to broader economic development goals: In the longer term: by reducing disease burdens, increasing workforce productivity In the near term: collaborative research with developing country partners can strengthen capacities for science and technology, contributing to growth and diversification of jobs, firms, and economies Harnessing AIDS Vaccine Investments for Economic Development Policy priority in this area:  Identify and advocate for best practices in maximizing development impact of global health R&D investments

9. Advocating for Strengthened Political and Financial Support Policy Advocacy Priorities:  Tracking available resources for AIDS vaccine R&D to make the case for increased and diversified investment  Demonstrating the spillover benefits of AIDS vaccine investment on development and health systems strengthening  Positioning AIDS vaccines as a tool to help achieve universal access and the MDGs

10. Annual Investments in HIV Vaccine R&D 2000-2009 US$ Millions

11. Conclusions  At a time of scientific progress and fiscal constraint, it is critical to sustain and increase political and financial support to continue advancing AIDS vaccine science.  Policy reforms are key to creating an enabling environment to accelerate AIDS vaccine R&D.  Identifying new funders and developing new R&D financing mechanisms are urgent priorities  Policies to spur scientific innovation and engage the private sector are also key priorities to accelerate aids vaccine science